On March 13, 2019 Ambry Genetics, a Konica Minolta Company (Ambry), and leading provider of clinical and research genetic testing, reported a new laboratory services agreement with Clovis Oncology Inc., a biopharmaceutical company which shares Ambry’s commitment to advancing precision medicine for cancer (Press release, Ambry Genetics, MAR 13, 2019, View Source [SID1234553909]). Through this laboratory services agreement, Ambry Genetics and Clovis Oncology seek to identify clinical trial patients who may benefit from Rubraca, a therapy currently approved in the U.S. and Europe in multiple advanced ovarian cancer settings.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Approximately 10 to 15% of ovarian cancer diagnoses are based on hereditary mutations of BRCA, meaning they are directly linked to mutations in the BRCA1 or BRCA2 genes passed on from a parent. Ambry’s genetic tests can identify mutations in these two genes, as well as related genes involved in the DNA repair pathway, thus enabling identification of potential risk, earlier diagnosis and more precise treatment.

"We are very excited to be working with the Clovis team, which is aligned with our precision medicine initiatives," said Brigette Tippin Davis, Ph.D., FACMG, Senior Vice President of Research & Development of Ambry Genetics, Inc. "Our mission is to help identify patients eligible for optimal therapies to improve outcomes and enhance quality of life."

Clovis chose to perform retrospective BRCA testing with Ambry Genetics, a high-quality genetics lab positioned to become a key player in the precision medicine space.